alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › acetylcholinesterase

acetylcholinesterase

234 studies tagged acetylcholinesterase, dated 1977-11-01 to 2026-10-25. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Integrated Transcriptomic and Structural Prioritization of Sulforaphane Targets in Neurodegeneration: A Multi-Dataset In Silico Study 2026-10-25
  2. Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling 2026-10-20
  3. DNA-Encoded Library-Guided Discovery of a First-in-Class Molecular Glue of the NOS1AP-SCRIB Complex in Alzheimer’s Disease Patient-Derived Neurons 2026-10-18

Studies

234 studies carry this tag.

Date range

1977 to 2026

Top journals

  • Research Square 9
  • Journal of medicinal chemistry 7
  • International journal of molecular sciences 6
  • Journal of Alzheimer's disease : JAD 6
  • Nature reviews. Drug discovery 6

154 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Integrated Transcriptomic and Structural Prioritization of Sulforaphane Targets in Neurodegeneration: A Multi-Dataset In Silico Study

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-10-25 Genetics

    Sulforaphane (SFN), a natural isothiocyanate from cruciferous vegetables, exerts neuroprotective effects through mechanisms extending beyond canonical Nrf2/ARE activation.

  2. Natural Sesquiterpenoids from Laggera pterodonta as bioactive Acetylcholinesterase Inhibitors: Insights from DFT, Molecular Docking, and ADMET Profiling

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-20 Treatments

    Alzheimer's disease continues to be one of the major critical neurodegenerative ailments of the modern era, with acetylcholinesterase (AChE) inhibition standing as a foundational therapeutic strategy.

  3. DNA-Encoded Library-Guided Discovery of a First-in-Class Molecular Glue of the NOS1AP-SCRIB Complex in Alzheimer’s Disease Patient-Derived Neurons

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-10-18 Biomarkers

    NOS1AP is an adaptor for neuronal nitric oxide synthase that engages several partner proteins and is implicated in Alzheimer’s disease.

  4. Simulating the Effects of Gamma Oscillation Treatment on Selective Neurotransmitters Using The Virtual Brain and Complex Pathway Simulator

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-06 Treatments

    Alzheimer's Disease (AD), the most common neurodegenerative disease in the world, is caused by a variety of factors that lead to neuronal injury and an alteration in neurotransmitter production and release.

  5. Magnetic Field–Enhanced Docosahexaenoic Acid Delivery for Acetylcholine Restoration in Alzheimer’s Disease: an In Silico Study

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-10-05 Prevention and risk

    Alzheimer’s Disease (AD) is characterised by the progressive depletion of Acetylcholine (ACh), a neurotransmitter essential for cognition and synaptic communication.

  6. Multi-Target Neuroprotection by Syzygium aromaticum Ethyl Acetate Fraction Against Mercuric Chloride-Induced Hippocampal Toxicity: Insights from Network Pharmacology, Molecular Docking, and In Vivo Evaluation

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. F1000Res 2026-10-05 Vascular contributions

    Mercury remains a pervasive environmental neurotoxicant strongly implicated in hippocampal oxidative injury and dementia-related cognitive decline, yet safe multi-target agents against its neurotoxicity remain limited.

  7. Substituent Effects on Electronic Properties and Acetylcholinesterase Inhibitory Potential of Donepezil Analogues: A DFT, Molecular Docking, and ADMET Study with Dynamics Validation of the Lead Candidate

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-05 Treatments

    Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is the leading cause of dementia in older people.

  8. Docking-Guided Design and Biological Evaluation of a Lead Convolvine-Based Acetylcholinesterase Inhibitor for Alzheimer's Disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-01 Treatments

    Alzheimer's disease (AD) is a progressive neurodegenerative condition marked by cognitive decline, memory loss, and cholinergic dysfunction [1].

  9. Discovery of Bavachin as a Dual Trk-A/Trk-B Agonist via Integrated Computational Screening and Experimental Validation

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-09-16 Disease mechanisms

    Neurotrophins regulate neuronal survival, differentiation, and synaptic plasticity through activation of tropomyosin receptor kinase (Trk) receptors, and their dysregulation is strongly implicated in neurodegenerative disorders, including Alzheimer’s disease.

  10. Biocatalytic Production of Galantamine in Yeast through Cytochrome P450 Optimization

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-09-11 Treatments

    Galantamine is a pharmaceutically relevant Amaryllidaceae alkaloid used for the treatment of Alzheimer’s disease.

  11. Structural optimization of coumarin-pyridine hybrid derivative salts as potent acetylcholinesterase inhibitors

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-03 Treatments

    Coumarins playing multiple roles in the life of plants also exhibit a wide range of positive effects for human health.

  12. Exploring the Molecular and Biochemical Mechanisms of Aromasin in Modulating COX-2/iNOS for Alzheimer’s Disease-Associated Synaptic Dysfunction: An In Silico Drug Repurposing Study

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-08-18 Drug development

    Cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) are central regulators of synaptic homeostasis, plasticity, and dysfunction during Alzheimer’s disease (AD) progression.

  13. Discovery of Natural Cholinesterase Inhibitors via Integrated Computational Studies using Labdane-Related Diterpenoids-based Pharmacophore Model and in-vitro studies

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-08-06 Treatments

    Alzheimer’s disease (AD) represents a progressively growing worldwide public health burden.

  14. Computational Screening of 1,348 FDA-Approved Drugs as Potential BACE1 Inhibitors for Alzheimer's Disease Drug Repurposing

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-07-28 Drug development

    Alzheimer's disease (AD) remains one of the most devastating and economically costly neurological conditions of the modern era, affecting over 55 million individuals worldwide with no approved disease-modifying therapy.

  15. Computational Screening of FDA-Approved Drugs as Potential BACE1 Inhibitors for Alzheimer's Disease Drug Repurposing

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-07-27 Treatments

    Alzheimer's disease is a progressive neurodegenerative disorder affecting over 55 million people worldwide, with no disease-modifying treatments currently approved.

  16. Network Pharmacology and Molecular Docking Uncover Novel Candidate Compound-Target Actions of Yokukansan (Yi-Gan San) in the Behavioral and Psychological Symptoms of Dementia

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-07-21 Clinical safety

    In total, 45 constituents were mapped to 181 human target genes through measured compound-target edges.

  17. Alzheimer's Disease: From Molecular Mechanisms to Promising Therapeutic Strategies

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. International journal of molecular sciences 2025-09-26 Disease mechanisms

    Alzheimer's disease (AD) is the most common cause of dementia worldwide, and there are still no strategies to slow or prevent its clinical progression.

  18. [Pharmacological Interventions in Dementia]

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. No shinkei geka. Neurological surgery 2025-09 Treatments

    Pharmacological interventions for dementia include medications aimed at alleviating its core symptom: cognitive dysfunction.

  19. Expression of Concern: Paladugu et al. Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease. Int. J. Mol. Sci. 2021, 22, 860

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. International journal of molecular sciences 2025-05-08 Drug development

    With this notice, the Internation Journal of Molecular Sciences Editorial Office states their awareness of the concerns regarding the integrity of a number of the figures published within this publication [...].

  20. Drug repurposing for Alzheimer's disease and other neurodegenerative disorders

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Nature communications 2025-02-19 Drug development

    Repurposed drugs provide a rich source of potential therapies for Alzheimer's disease (AD) and other neurodegenerative disorders (NDD).

  21. Seizing the opportunity to therapeutically address neuronal hyperexcitability in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Alzheimer's disease : JAD 2025-01-09 Drug development

    Seizures in people with Alzheimer's disease are increasingly recognized to worsen disease burden and accelerate functional decline.

  22. A Self-Reinforced "Microglia Energy Modulator" for Synergistic Amyloid-β Clearance in Alzheimer's Disease Model

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Angewandte Chemie (International ed. in English) 2025-01-07 Drug development

    Microglial phagocytosis is a highly energy-consuming process that plays critical roles in clearing neurotoxic amyloid-β (Aβ) in Alzheimer's disease (AD).

  23. Galantamine-Memantine Combination in the Treatment of Parkinson's Disease Dementia

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Brain sciences 2024-11-21 Treatments

    Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects over 1% of population over age 60.

  24. Neuropathology meets chemical and genetic pathology head-on: a personal perspective

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Pathology 2024-11-20 Biomarkers

    Medical science has made revolutionary discoveries around the nosology and aetiology of the neurodegenerative diseases.

  25. Repurposing doxycycline for Alzheimer's treatment: Challenges from a nano-based drug delivery perspective

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Brain, behavior, & immunity - health 2024-10-25 Drug development

    Drug repurposing, also known as drug repositioning, involves identifying new applications for drugs whose effects in a disease are already established.

  26. Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2024-10-13 Drug development

    Behavioral analyses on APP/PS1 mice demonstrated that Semaglutide improved the cognitive capabilities, particularly in the learning and memory domains.

  27. Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive Disorders

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Aging and disease 2024-10-01 Treatments

    The prevalence of neurocognitive disorders (NCD) increases every year as the population continues to age, leading to significant global health concerns.

  28. Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Signal transduction and targeted therapy 2024-08-23 Treatments

    Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant and escalating global challenges.

  29. Sulfopropanoic acid derivatives for treating neurodegenerative disorders: a patent spotlight

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Pharmaceutical patent analyst 2024-06-20 Clinical trials

    The patent introduces a class of agents that target amyloid aggregation, and subsequently, reduce amyloid β-oligomer neurotoxicity.

  30. Drug repurposing for neurodegenerative diseases

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Progress in molecular biology and translational science 2024-05-22 Drug development

    Neurodegenerative diseases (NDDs) are neuronal problems that include the brain and spinal cord and result in loss of sensory and motor dysfunction.

  31. Diaminocyclopentane - l-Lysine Adducts: Potent and selective inhibitors of human O-GlcNAcase

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Bioorganic chemistry 2024-05-18 Drug development

    A new class of compounds, namely highly substituted diaminocyclopentane-l-lysine adducts, have been discovered as potent inhibitors of O-GlcNAcase, an enzyme crucial for protein de-O-glycosylation.

  32. Dual Drug Repurposing: The Example of Saracatinib

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. International journal of molecular sciences 2024-04-22 Drug development

    Saracatinib (AZD0530) is a dual Src/Abl inhibitor initially developed by AstraZeneca for cancer treatment; however, data from 2006 to 2024 reveal that this drug has been tested not only for cancer treatment, but also for the treatment of other diseases.

  33. Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of controlled release : official journal of the Controlled Release Society 2024-02-01 Costs and economics

    Alzheimer's disease (AD), is a neurodegenerative disorder that escalates with time, exerting a significant impact on physical and mental health and leading to death.

  34. Drug Repositioning: A Monetary Stratagem to Discover a New Application of Drugs

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Current drug discovery technologies 2024 Drug development

    Drug repurposing, also referred to as drug repositioning or drug reprofiling, is a scientific approach to the detection of any new application for an already approved or investigational drug.

  35. Transdermal Therapeutic Systems for the Treatment of Alzheimer's Disease: A Patent Review

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. CNS & neurological disorders drug targets 2024 Treatments

    TTSs present some limit factors in terms of absorption due to skin physiology and the size of the molecules with established limits of percutaneous penetration (molecular mass of 500 g/mol and log P of 5).

  36. Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Tissue barriers 2023-12-14 Drug development

    We find that IRAs can cross the BBB by two separate processes; one that is fast and one that is slow.

  37. Huntington's Disease Drug Development: A Phase 3 Pipeline Analysis

    ✓ Peer-reviewed alzhub usefulness score 70 out of 100. Pharmaceuticals (Basel, Switzerland) 2023-10-24 Clinical trials

    Huntington's Disease (HD) is a severely debilitating neurodegenerative disorder in which sufferers exhibit different combinations of movement disorders, dementia, and behavioral or psychiatric abnormalities.

  38. Galantamine-memantine hybrids for Alzheimer's disease: The influence of linker rigidity in biological activity and pharmacokinetic properties

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. European journal of medicinal chemistry 2023-09-12 Treatments

    Neurodegenerative processes characterizing Alzheimer's disease (AD) are strictly related to the impairment of cholinergic and glutamatergic neurotransmitter systems which provoke synaptic loss.

  39. Carbamate as a potential anti-Alzheimer's pharmacophore: A review

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Drug development research 2023-09-11 Treatments

    Alzheimer's disease (AD) is a progressive age-related neurodegenerative brain disorder, which leads to loss of memory and other cognitive dysfunction.

  40. Drug repurposing on Alzheimer's disease through modulation of NRF2 neighborhood

    ✓ Peer-reviewed alzhub usefulness score 70 out of 100. Redox biology 2023-09-07 Drug development

    Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder and the most common cause of cognitive decline.

  41. Tryptamine: A privileged scaffold for the management of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Drug development research 2023-09-07 Treatments

    Alzheimer's disease (AD) is a chronic and irreversible neurodegenerative disease associated with aging.

  42. Highly functionalized diaminocyclopentanes: A new route to potent and selective inhibitors of human O-GlcNAcase

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Bioorganic chemistry 2023-08-28 Drug development

    A new class of compounds inhibiting de-O-glycosylation of proteins has been identified.

  43. Current and future therapeutic strategies for Alzheimer's disease: an overview of drug development bottlenecks

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Frontiers in aging neuroscience 2023-08-03 Treatments

    Alzheimer's disease (AD) is the most common chronic neurodegenerative disease worldwide.

  44. ABC Transporter C1 Prevents Dimethyl Fumarate from Targeting Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Biology 2023-06-29 Drug development

    Alzheimer's disease (AD), the leading cause of dementia, is a growing health issue with very limited treatment options.

  45. Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer's disease patients

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of translational medicine 2023-05-20 Drug development

    We identified glutaminase as a promising drug target.

  46. Combination of acetylcholinesterase inhibitors and NMDA receptor antagonists increases survival rate in soman-poisoned mice

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Toxicology mechanisms and methods 2023-04-19 Treatments

    Organophosphorus nerve agents pose a global threat to both military personnel and civilian population, because of their high acute toxicity and insufficient medical countermeasures.

  47. Drug Repurposing to Inhibit Histamine N-Methyl Transferase

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Molecules (Basel, Switzerland) 2023-01-06 Drug development

    Lower activity of the histaminergic system is associated with neurological disorders, including Alzheimer's disease (AD).

  48. Foresee Novel Targets for Alzheimer's Disease by Investigating Repurposed Drugs

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. CNS & neurological disorders drug targets 2023 Drug development

    Drugs like Zileuton, Salbutamol, Baricitinib, Carmustine, Paclitaxel, and Nilotinib were observed to be involved in regulation of neurotransmitters.

  49. Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Ageing research reviews 2022-12-16 Drug development

    Alzheimer's disease (AD) is a multivariate and diversified disease and affects the most sensitive areas of the brain, the cerebral cortex, and the hippocampus.

  50. Drug repurposing using meta-analysis of gene expression in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 70 out of 100. Frontiers in neuroscience 2022-11-10 Drug development

    Reversal genes and the candidate compounds were identified by the leave-one-out cross-validation procedure.

From across this tag

8 of the 234 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.

All topic tags with their study counts